stent

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMACEstent thrombosis

antithrombotics

not classified
DECLARE-LONG II , 2011      -
EXCELLENT, 2011      NCT6-month dual antiplatelet therapy12 months dual antiplateletnegative-100%
PRODIGY, 2011      NCT24 months of dual antiplatelet treatment6 months dual antiplateletnegative 7%-14%
WOEST    NCTtriple therapydual antiplatelet therapy -
RESET    NCTEndeavor stent and three months of DAPTstandard 12-month DAPT and other DESnegative50%
DES-LATE, 2010    NCTprolonged dual antiplatelet therapy12 months dual antiplateletRisk of bias negative65%24%
ISAR-SAFE, 2009      NCT12 months dual antiplatelet6 months dual antiplateletLow risk of bias -
CILON-T, 2010     triple antiplateletdual antiplatelet therapyExploratory negative-7%-40%
cilostazol
Kunishima, 1997     cilostazolaspirinnegative-100%
Sekiya, 1998     cilostazol + aspirinaspirinnegative-100%
Kozuma, 2001     cilostazol + aspirinticlopidine + aspirinnegative-100%
Ochiai, 1999     cilostazol + aspirinticlopidine + aspirinnegative
Park, 1999     cilostazol + aspirinticlopidine + aspirinnegative97%
Yoon, 1999     cilostazol + aspirinticlopidine + aspirinnegative-32%
Kamishirado, 2002     cilostazol + aspirinticlopidine + aspirinnegative-100%
clopidogrel
REAL-LATE, ZEST-LATE, 2010      NCTclopidogrel+aspirinaspirinnegative24%
GRAVITAS, 2011      NCThigh-dose clopidogrelnormal-dose clopidogrelRisk of bias negative-38%
Müller, 2000     clopidogrel + aspirinticlopidine + aspirinnegative78%
CLASSICS, 2000     clopidogrel + aspirinticlopidine + aspirinnegative31%
TOPPS, 2001     clopidogrel + aspirinticlopidine + aspirinnegative-16%
Piamsomboon, 2001   clopidogrel + aspirinticlopidine + aspirinnegative-100%
ticlopidine
STARS (vs aspirin), 1998     ticlopidine + aspirinaspirinsuggesting-85%
Hall, 1996     ticlopidine + aspirinaspirinnegative98%
FANTASTIC, 1998     ticlopidine + aspirincoumadin + aspirinnegative-30%
ISAR, 1996     ticlopidine + aspirincoumadin + aspirinsuggesting-75%
Foussas, 2000   ticlopidine + aspirincoumadin + aspirinsuggesting-69%
MATTIS, 1998     ticlopidine + aspirincoumadin + aspirinnegative-49%
STARS (vs coumadin+asp), 1998     ticlopidine + aspirincoumadin + aspirinsuggesting-80%

dual antiplatelet therapy

not classified
OPTIMIZE, 2013      NCT3 months DAPT 12 months DAPTRisk of bias -
EXCELLENT, 2011      NCT6-month dual antiplatelet therapy12 months dual antiplateletnegative-100%
PRODIGY, 2011      NCT24 months of dual antiplatelet treatment6 months dual antiplateletnegative 7%-14%
RESET    NCTEndeavor stent and three months of DAPTstandard 12-month DAPT and other DESnegative50%
DES-LATE, 2010    NCTprolonged dual antiplatelet therapy12 months dual antiplateletRisk of bias negative65%24%
ISAR-SAFE, 2009      NCT12 months dual antiplatelet6 months dual antiplateletLow risk of bias -
clopidogrel
REAL-LATE, ZEST-LATE, 2010      NCTclopidogrel+aspirinaspirinnegative24%
GRAVITAS, 2011      NCThigh-dose clopidogrelnormal-dose clopidogrelRisk of bias negative-38%